| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Histone deacetylase 8; HD8; HDAC8; HDACL1; CDA07; RPD 3; MRXS6;;HDAC8 |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human HDAC8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于HDAC8抗体的3篇参考文献及其摘要概括：
1. **《Histone deacetylase 8 is aberrantly overexpressed in human cancer cells》**
- **作者**：Waltregny, D. et al. (2005)
- **摘要**：该研究首次报道了HDAC8在多种人类癌细胞系及肿瘤组织中的异常高表达，并通过特异性抗体验证了其蛋白水平，提示HDAC8可能成为癌症治疗的潜在靶点。
2. **《HDAC8 mutations in Cornelia de Lange syndrome affect cohesin acetylation and gene regulation》**
- **作者**：Deardorff, M.A. et al. (2012)
- **摘要**：研究揭示了HDAC8基因突变导致Cornelia de Lange综合征的分子机制，利用HDAC8抗体证实突变体蛋白功能缺失，影响染色质修饰和基因表达调控。
3. **《Structural basis for the selective inhibition of HDAC8》**
- **作者**：Rettig, I. et al. (2015)
- **摘要**：通过解析HDAC8的晶体结构，研究者开发了高选择性抑制剂，并利用HDAC8抗体验证了抑制剂对酶活性的抑制效果，为靶向治疗提供了结构基础。
4. **《The HDAC family, its ligands and functional diversity in cancer》**
- **作者**：Haberland, M. et al. (2009)
- **摘要**：综述了HDAC家族各亚型(包括HDAC8)的生物学功能及抗体工具在癌症研究中的应用，强调HDAC8在表观遗传调控中的独特作用。
这些文献覆盖了HDAC8在疾病机制、结构功能及抗体应用方面的关键研究。
**Background of HDAC8 Antibody**
Histone deacetylase 8 (HDAC8) is a member of the class I HDAC family, enzymes that regulate gene expression by removing acetyl groups from histone and non-histone proteins. HDAC8 is distinct in its structural and functional characteristics, featuring a unique catalytic domain and substrate specificity compared to other HDACs. Primarily localized in the nucleus and cytoplasm, HDAC8 plays roles in cell proliferation, differentiation, and apoptosis by modulating chromatin structure and protein interactions.
HDAC8 is implicated in various diseases, including cancers (e.g., neuroblastoma, leukemia), neurological disorders, and Cornelia de Lange syndrome (CdLS), where mutations in *HDAC8* disrupt developmental pathways. Its dysregulation is often linked to aberrant epigenetic modifications, making it a therapeutic target. HDAC8-selective inhibitors are under investigation for their anti-tumor and neuroprotective potential.
HDAC8 antibodies are essential tools for studying its expression, localization, and function. They are used in techniques like Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to assess HDAC8 levels in tissues or cell lines. High-specificity antibodies are critical due to structural similarities among HDAC family members. Additionally, HDAC8 antibodies aid in evaluating the efficacy of HDAC inhibitors in preclinical research, bridging mechanistic insights with therapeutic development.
In summary, HDAC8 antibodies advance our understanding of epigenetic regulation and disease mechanisms, supporting both basic research and drug discovery efforts.
×
